Posts belonging to Category Uncategorized
Cytokinetics, Incorporated announced today the initiation of a first-time-in-humans, Phase I clinical trial of CK-2127107 in healthy male volunteers. Cytokinetics is developing CK-2127107, a novel small molecule activator of the fast skeletal muscle troponin complex, for the potential improvement of skeletal muscle function in diseases and medical conditions associated with neuromuscular dysfunction, muscular weakness, and/or muscle fatigue. Like tirasemtiv, the lead drug candidate from the company’s skeletal muscle activator program, CK-2127107 slows the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium.
MDA has awarded a $400,000 grant to National Institutes of Health (NIH) Laboratory of Neurogenetics researchers to perform exome sequencing on samples taken from 1,000 people with sporadic amyotrophic lateral sclerosis (ALS). The project will be led by neurologist Bryan Traynor, head of the Neuromuscular Diseases Research Group at the NIH in Bethesda, Md.
This morning, Eric Nolet, general director of the ALS Foundation of the Netherlands, opened the trading day by sounding the bell to highlight World ALS Day — or Wereld ALS Dag.
Saneron will use the cells for future clinical trials to study possible therapies for restoring brain tissue in patients suffering from Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), also known as “Lou Gehrig’s disease,” and the effects of stroke.
St. Louis- Upon hearing about his diagnosis of amyotrophic lateral sclerosis (ALS) in September 2009, Bob Stehlin vowed to fight the disease with all his strength. He started the RASCALS Foundation to bolster medical and social service programs for others with the fatal neurodegenerative disease who live in Eastern Missouri as well as in Central [...]
This Valentine’s Day, please make your tax-deductible contribution or micro-donation to the RASCALS Foundation.
Too much needs to be done.
No amount is too small.
The U.S. Department of Veterans Affairs published regulations that would increase from 30% to 100% the minimum disability rating automatically provided to all veterans with ALS who qualify for service connected benefits.
According to founder and president, Robert Stehlin, the award was created to “recognize those who have soared above and beyond the call of duty on behalf of the Foundation, and all patients with amyotrophic lateral sclerosis.”
L-R Anne Fann, Research Coordinator, Robert Stehlin, RASCALS Founder, Dr. Hayat, Clinical Director, Greg Reagan, RASCALS Treasurer
St. Louis, Missouri,
August 2, 2011
Robert Stehlin, a patient of SLUCare neurologist Dr. Ghazala Hayat, last week presented a check for $9,000 to help fund her research of Lou Gehrig’s disease, which is a degenerative neurological condition also [...]
“The big guys like cancer and AIDS get the bulk of the research money,” he says adding that most of the other donation goes toward medical care and bettering quality of living for patients.